HONG KONG – China-focused biopharmaceutical stocks have not been left out of the bull markets in Hong Kong and Shanghai, which are being powered by an influx of capital and strong company performances. The Hong Kong market in particular has been pushed up over the last week as the Shanghai-Hong Kong Stock Connect Scheme, launched in November 2014, facilitated an influx of capital from Mainland China into the market.
Astellas Pharma Inc., of Tokyo, appointed Shontelle Dodson vice president, medical excellence, medical affairs. Dodson will be based at the global headquarters for the company's medical and development functions in Northbrook, Ill.
SHANGHAI – Increasingly, Chinese biotechs are finding the time is right to take their pipelines to the U.S., and Sihuan Pharmaceutical Holdings Group Ltd., China's fourth largest pharma company (in hospital sales), is the latest to take the leap.
NEW DELHI – India is taking a series of steps to power its biopharmaceutical industry that could lead to more investment, better infrastructure for drug development and a visible reduction in red tape. One of the more significant such steps is the development of a series of biotech and pharmaceutical industry clusters that could help speed up drug discovery and development.
HONG KONG – A Sino-U.S. research collaboration has determined the atomic structure of the G protein-coupled (GPC) P2Y1 receptor, which plays a key role in thrombus formation, challenging conventional concepts of drug action at GPC receptors and opening the door for future new drug discovery and development.
HONG KONG – In another blow to the operations of multinational pharmaceutical companies in China, Pfizer Inc. may have to suspend its vaccine business temporarily as it shifts from Prevenar 7 to Prevenar 13.
Wuxi Pharmatech (Cayman) Inc., of Shanghai, said its wholly owned subsidiary, Syntheall Pharmaceutical Co. Ltd. (STA), received approval from China's National Equities Exchange and Quotations to list its shares on the New Third Board, China's over-the-counter stock exchange, beginning April 3.
SINGAPORE – South Korea and India are likely to remain the leading players in the biosimilars space in Asia and widen the lead they have on China, which remains a distant third.
SHANGHAI – U.S.-China biotech CASI Pharmaceuticals Inc. initiated dosing in Chinese patients with ENMD-2076, a selective angiogenic kinase inhibitor, in a phase II study for triple-negative breast cancer (TNBC). That marks CASI's first foray with ENMD-2076 in China.
RSS